Progesterone is sometimes added to feminizing hormone therapy alongside estrogen and an anti-androgen, though its role remains one of the most debated topics in transgender healthcare. In cisgender women, progesterone plays a clear part in breast maturation, menstrual cycling, and pregnancy. For trans women, the picture is less settled: some effects have biological plausibility and anecdotal support, while clinical trial data so far has been limited and often inconclusive.
How Progesterone Affects Breast Development
This is the most commonly cited reason trans women seek progesterone. During typical female puberty, estrogen drives the initial expansion of breast tissue, while progesterone stimulates differentiation of the mammary glands, the branching of milk ducts, and the enlargement of the areola. Without progesterone, breast development in trans women on estrogen alone tends to plateau at an earlier stage of maturity, often around Tanner stage 3, with smaller areolae (under about 2.5 cm) and less fullness in the breast’s rounded shape. The hope is that adding progesterone can push development further, toward stages 4 and 5, where the areola enlarges beyond 3 cm and the breast takes on a more mature contour.
The biological logic is sound, but the clinical evidence is thin. A recent randomized controlled trial found that adding micronized progesterone to feminizing hormone therapy did not produce a statistically significant change in Tanner stage compared to standard care. However, critics note that the study used a relatively low dose, followed participants for only a short period, and many participants were also taking cyproterone acetate, a synthetic progestogen that may have muddied the results. No large, long-term trial has definitively answered whether progesterone improves breast outcomes for trans women. Many clinicians still prescribe it based on the well-established role it plays in cisgender breast development, paired with the consistent anecdotal reports from trans women who feel it helped.
Testosterone Suppression
Progesterone can help lower testosterone through two distinct mechanisms. First, it signals the brain’s hormonal control center to dial back production of luteinizing hormone, which is the chemical messenger that tells the testes to produce testosterone. Less luteinizing hormone means less testosterone synthesis. Second, progesterone blocks an enzyme called 5-alpha reductase, which converts testosterone into a more potent form called DHT. DHT is responsible for many masculinizing effects in skin, hair, and other tissues, so blocking its production can help reduce those effects.
These anti-androgen properties are considered moderate. Progesterone is not strong enough to replace a dedicated anti-androgen for most people, but it can complement one. For trans women who want to reduce their anti-androgen dose or who experience side effects from medications like spironolactone, progesterone’s additional testosterone-lowering action may offer some flexibility in their regimen.
Sleep and Mood
Many trans women report that progesterone improves their sleep and reduces anxiety, and there is a plausible biological explanation. Progesterone is metabolized in the body into compounds that interact with GABA receptors in the brain, the same system targeted by anti-anxiety and sleep medications. In studies of cisgender postmenopausal women, micronized progesterone has been shown to reduce the time it takes to fall asleep and improve self-reported sleep quality. A reduction in anxiety has also been reported in women with premenstrual mood disorders.
When researchers specifically tested this in trans women, though, the results were less clear. A prospective controlled study found high baseline levels of sleep impairment and psychological distress among trans participants, but 100 mg of oral progesterone over three months did not produce a statistically significant improvement compared to standard care. That said, within the progesterone group, 35% of participants showed individual improvement on a validated distress scale, compared to 21% in the control group. The difference wasn’t large enough to reach statistical significance in a small study, which leaves the question open. The sleep and mood benefits may be real for some individuals but are not guaranteed.
Effects on Libido
One common concern is whether progesterone affects sex drive. The available evidence leans in one direction: progesterone does not appear to boost libido, and at higher doses it may reduce it. In cisgender women, progesterone levels are consistently negatively associated with sexual desire. During pregnancy, when progesterone levels are extremely high, sexual desire typically decreases. Studies in primates show a similar pattern, with progesterone reducing sexual receptivity when added to estrogen.
For trans women, this means progesterone is unlikely to help if low libido is a concern. At the typical doses used in feminizing therapy, the effect on sex drive is probably modest for most people. Some trans women report no noticeable change, while others notice a decrease. If you’re experiencing low libido on your current regimen, adding progesterone is unlikely to help and could potentially make things worse.
Fat Redistribution
Progesterone influences fat storage and metabolism, which has led to speculation that it might enhance feminine fat distribution in the hips, thighs, and buttocks. However, the evidence for this specific effect is weak. A cohort study using CT scans to evaluate whether progesterone influenced the redistribution of facial fat volumes in 45 patients found that it did not have a substantial influence on the process. No well-designed studies have demonstrated that progesterone meaningfully changes body fat distribution beyond what estrogen and testosterone suppression already accomplish.
Bone Health
Progesterone has been proposed to support bone formation in trans women. In cisgender women, progesterone stimulates the cells responsible for building new bone tissue, and adequate levels are considered important for long-term skeletal health. For trans women, who face potential bone density risks from testosterone suppression, this is a relevant consideration. However, direct evidence measuring bone mineral density changes from adding progesterone to feminizing hormone therapy is lacking. The theoretical benefit is extrapolated from data in cisgender women rather than confirmed in trans-specific research.
When Progesterone Is Typically Started
There is no universal guideline on when to introduce progesterone. The general approach to feminizing hormone therapy combines an estrogen with an anti-androgen, and progesterone is sometimes added later as an optional component. Many clinicians who prescribe it suggest waiting until breast development has been underway for at least a year or two on estrogen, mirroring the natural timing in female puberty where progesterone levels rise after initial breast budding. The idea is to let estrogen do its initial work of expanding breast tissue before introducing progesterone to promote further maturation. Some clinicians use progesterone earlier as part of a strategy to help suppress testosterone, particularly if other anti-androgens are causing side effects.
Micronized progesterone (sometimes called “bioidentical” progesterone) is generally preferred over synthetic progestins in feminizing therapy. It is typically taken orally, often at bedtime to take advantage of its sedative properties. The optimal dose and route of administration for trans women have not been established through rigorous research, so prescribing practices vary significantly between providers.
The Bottom Line on Evidence
Progesterone occupies an unusual space in feminizing hormone therapy. Its biological roles are well understood from research in cisgender women, but translating those findings to trans women has proven difficult. The existing clinical trials in trans populations have been small, short, and often complicated by confounding factors. This does not mean progesterone is ineffective. It means we don’t yet have strong enough data to say with certainty what it does or doesn’t do for most trans women. Many clinicians prescribe it based on biological reasoning and patient-reported benefits, while others hold off due to the lack of definitive evidence. If you’re considering progesterone, the decision is best made in conversation with your prescribing provider, weighing the theoretical benefits against your individual goals and health profile.